AtriCure 3Q 2026: Revenue $154.45M, EPS $0.08— 10-Q Summary
AtriCure reported Q3 2026 revenue of $154.45M, up 15% YoY, and net income of $4.06M, reversing a prior-year loss. EPS was $0.08 vs. a loss of $0.01. Nine-month revenue rose 14%, led by U.S. growth. Pain management and open ablation revenue increased, while hybrid procedures declined. New product launches and clinical trial updates were announced.
How this was made
The 30-second read
Why it matters
Earnings beat on revenue and EPS may trigger short‑term buying, but product mix shifts and declining ablation lines warrant caution.
Market read
First‑report earnings for a micro‑cap medical‑device company; modest upside potential for traders.
What to watch
The upcoming FDA clearance for the 30 mm FLEX‑Mini may delay near‑term upside if launch timing slips.
Background
AtriCure is a medical‑device company focused on cardiac ablation technologies. The 10‑Q filing provides its Q3 2026 financials and product updates.
Ticker impact
Q3 2026 earnings released with revenue $154.45M (+15% YoY) and EPS $0.08, a first‑report earnings disclosure.
likely modest upside as the market prices in the earnings beat
First‑report earnings for a micro‑cap; beat on revenue and EPS suggests short‑term buying pressure.
Market effects
Positive earnings may lift the cardiac device sector, indicating demand growth in the U.S. market.
U.S. investors may view the results as a sign of strength in domestic medical‑device firms.
Limited; the impact is primarily confined to U.S. small‑cap healthcare investors.
Counterpoint
Despite revenue growth, the decline in minimally invasive ablation could signal longer‑term margin pressure.
Key entities
- companyAtriCure, Inc.
Medical‑device firm reporting Q3 2026 results.
